Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.33 |
| ▸ | CDK1 | P06493 | 3/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8090131 | 0.82 | MAPT (0.43) | NOTUMPDPK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22261804 | 0.78 | NISCH (0.42) | NISCHNOTUMALDH1A1RAB9ANPC1 | |
| SCHEMBL22261807 | 0.78 | CCNB2 (0.37) | NOTUMRAB9ANPC1CCNB2CDK1 | |
| SCHEMBL22261806 | 0.78 | CCNB2 (0.37) | NOTUMALDH1A1RAB9ANPC1CCNB2 | |
| SCHEMBL9955444 | 0.77 | NISCH (0.40) | NISCHALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7500881 | 0.77 | CYP17A1 (0.42) | NISCHNOTUMGSK3BPRKACATAAR1 | |
| SCHEMBL1335904 | 0.74 | KDM4E (0.52) | ALDH1A1RAB9ANPC1CCNB2CDK1 | |
| SCHEMBL10921966 | 0.74 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL22261802 | 0.74 | CLK4 (0.48) | NISCHALDH1A1RAB9ANPC1CCNB2 | |
| SCHEMBL584984 | 0.71 | KDM4E (0.31) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166098-A | Triazine compound, material for organic electroluminescent element, and organic electroluminescent element | 东曹株式会社 | 2021-07-23 | — | — | CN | claimed |
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | claimed |
| WO-2015114030-A1 | ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF HEART DISEASES | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2015-08-06 | — | — | WO | claimed |
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | claimed |
| EP-2493894-B1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-29 | — | — | EP | claimed |
| EP-2493893-B1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | claimed |
| EP-2491034-B1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-18 | — | — | EP | claimed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | claimed |
| US-8278320-B2 | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | claimed |
| EP-2493893-A1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | claimed |
| EP-1815867-A1 | COMBINATION DRUG FOR TREATING AUTOIMMUNE DISEASE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-08-08 | — | — | EP | claimed |
| JP-2007515442-A | — | — | 2007-06-14 | — | — | JP | claimed |
| EP-1709049-A1 | BICYCLIC IMIDAZOLE COMPOUNDS, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-10-11 | — | — | EP | claimed |
| EP-0979226-B1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-11-09 | — | — | EP | claimed |
| WO-2005063750-A1 | BICYCLIC IMIDAZOLE COMPOUNDS, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | WO | claimed |
| US-20050143377-A1 | Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-30 | — | — | US | claimed |
| US-6100260-A | ((3-(1-(2-FLUORO-BIPHENYL-4-YL)-ETHYL)-ISOXAZOL-5-YLIMINO) -MORPHOLIN-4-YL-M ETHYL)-AMINE, FOR EXAMPLE; ADMINISTERING TO TREAT AUTOIMMUNE DISEASES AND INFLAMMATION | SUMITOMO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-08 | — | — | US | claimed |
| EP-0979226-A1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-02-16 | — | — | EP | claimed |
| WO-1998047880-A1 | ISOXAZOLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-10-29 | — | — | WO | claimed |
| EP-0007678-B1 | OXIME ETHERS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ACF CHEMIEFARMA NV (NL) | 1983-03-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143377-A1 | Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | MTOR 1416/4885ADK 1501/4885NISCH 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.